Incyte | Passività Correnti





Passività Correnti Cambiamento Data
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Agenus USD 287.13M 52.57M 2025-09
Agios Pharmaceuticals USD 82.21M 7.45M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Amgen USD 25.49B 3.7B 2025-12
BioCryst Pharmaceuticals USD 190.24M 13.08M 2025-09
Biogen USD 3.35B 59.4M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Eli Lilly USD 35.23B 4.91B 2025-12
Exelixis USD 405.64M 31.86M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
Incyte USD 1.52B 176.44M 2025-12
Ionis Pharmaceuticals USD 783M 120.46M 2025-12
MacroGenics USD 44.47M 5.47M 2025-09
Merck USD 28.63B 2.59B 2025-09
Moderna USD 1.99B 306M 2025-12
Nektar Therapeutics USD 66.34M 5.05M 2025-09
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Novartis USD 32B 286M 2025-09
Novartis USD 32B 286M 2025-09
Pfizer USD 36.6B 1.13B 2025-09
PTC Therapeutics USD 968.43M 102.18M 2025-12
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
Vertex Pharmaceuticals USD 3.86B 614.1M 2025-12


Incyte Passività Correnti - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.